EHMT2 and breast carcinoma: In breast cancer, the combined inhibition of G9a and EZH2 by UNC0642 and GSK343, respectively, had a greater effect on gene transcription, inhibiting cancer cell proliferation to a larger extent compared to either drug alone [121].